147 related articles for article (PubMed ID: 27334278)
21. Hydrogenated Soy Phosphatidylcholine Liposomes Stimulate Differential Expression of Chemokines And Cytokines by Rat Alveolar Macrophages In Vitro.
Ibrahim JP; Dao N; Haque S; Phipps S; Whittaker MR; Kaminskas LM
J Pharm Sci; 2024 May; 113(5):1395-1400. PubMed ID: 38460572
[TBL] [Abstract][Full Text] [Related]
22. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats.
Wijagkanalan W; Kawakami S; Takenaga M; Igarashi R; Yamashita F; Hashida M
J Control Release; 2008 Jan; 125(2):121-30. PubMed ID: 18037185
[TBL] [Abstract][Full Text] [Related]
23. Real-time in vivo imaging of surface-modified liposomes to evaluate their behavior after pulmonary administration.
Murata M; Tahara K; Takeuchi H
Eur J Pharm Biopharm; 2014 Jan; 86(1):115-9. PubMed ID: 24055689
[TBL] [Abstract][Full Text] [Related]
24. Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant.
Anabousi S; Kleemann E; Bakowsky U; Kissel T; Schmehl T; Gessler T; Seeger W; Lehr CM; Ehrhardt C
J Nanosci Nanotechnol; 2006; 6(9-10):3010-6. PubMed ID: 17048512
[TBL] [Abstract][Full Text] [Related]
25. In vivo and in vitro uptake of surfactant lipids by alveolar type II cells and macrophages.
Poelma DL; Zimmermann LJ; Scholten HH; Lachmann B; van Iwaarden JF
Am J Physiol Lung Cell Mol Physiol; 2002 Sep; 283(3):L648-54. PubMed ID: 12169585
[TBL] [Abstract][Full Text] [Related]
26. Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats.
Sun J; Deguchi Y; Tauchi Y; He Z; Cheng G; Morimoto K
Eur J Pharm Biopharm; 2006 Oct; 64(2):238-45. PubMed ID: 16875808
[TBL] [Abstract][Full Text] [Related]
27. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections.
Chono S; Tanino T; Seki T; Morimoto K
J Control Release; 2008 Apr; 127(1):50-8. PubMed ID: 18230410
[TBL] [Abstract][Full Text] [Related]
28. Particle size-dependent triggering of accelerated blood clearance phenomenon.
Koide H; Asai T; Hatanaka K; Urakami T; Ishii T; Kenjo E; Nishihara M; Yokoyama M; Ishida T; Kiwada H; Oku N
Int J Pharm; 2008 Oct; 362(1-2):197-200. PubMed ID: 18586076
[TBL] [Abstract][Full Text] [Related]
29. Study of the charge distribution on liposome particles aerosolized by air-jet atomization.
Chadha TS; Chattopadhyay S; Venkataraman C; Biswas P
J Aerosol Med Pulm Drug Deliv; 2012 Dec; 25(6):355-64. PubMed ID: 22551083
[TBL] [Abstract][Full Text] [Related]
30. Liposome-based drug delivery to alveolar macrophages.
Vyas SP; Khatri K
Expert Opin Drug Deliv; 2007 Mar; 4(2):95-9. PubMed ID: 17335407
[TBL] [Abstract][Full Text] [Related]
31. Increased fibronectin expression in lung in the setting of chronic alcohol abuse.
Burnham EL; Moss M; Ritzenthaler JD; Roman J
Alcohol Clin Exp Res; 2007 Apr; 31(4):675-83. PubMed ID: 17374047
[TBL] [Abstract][Full Text] [Related]
32. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats.
Wang XY; Ishida T; Ichihara M; Kiwada H
J Control Release; 2005 May; 104(1):91-102. PubMed ID: 15866337
[TBL] [Abstract][Full Text] [Related]
33. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
[TBL] [Abstract][Full Text] [Related]
34. Unravelling Heterogeneities in Complement and Antibody Opsonization of Individual Liposomes as a Function of Surface Architecture.
Münter R; Stavnsbjerg C; Christensen E; Thomsen ME; Stensballe A; Hansen AE; Parhamifar L; Kristensen K; Simonsen JB; Larsen JB; Andresen TL
Small; 2022 Apr; 18(14):e2106529. PubMed ID: 35187804
[TBL] [Abstract][Full Text] [Related]
35. A common pathway for the uptake of surfactant lipids by alveolar cells.
Poelma DL; Ju MR; Bakker SC; Zimmermann LJ; Lachmann BF; van Iwaarden JF
Am J Respir Cell Mol Biol; 2004 May; 30(5):751-8. PubMed ID: 14644915
[TBL] [Abstract][Full Text] [Related]
36. PEG modification on (111)In-labeled phosphatidyl serine liposomes for imaging of atherosclerotic plaques.
Ogawa M; Uchino R; Kawai A; Kosugi M; Magata Y
Nucl Med Biol; 2015 Mar; 42(3):299-304. PubMed ID: 25533763
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary effects of chronic exposure to liposome aerosols in mice.
Myers MA; Thomas DA; Straub L; Soucy DW; Niven RW; Kaltenbach M; Hood CI; Schreier H; Gonzalez-Rothi RJ
Exp Lung Res; 1993; 19(1):1-19. PubMed ID: 8440200
[TBL] [Abstract][Full Text] [Related]
38. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery.
Chono S; Fukuchi R; Seki T; Morimoto K
J Control Release; 2009 Jul; 137(2):104-9. PubMed ID: 19351549
[TBL] [Abstract][Full Text] [Related]
39. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages.
Lee WH; Loo CY; Traini D; Young PM
Expert Opin Drug Deliv; 2015 Jun; 12(6):1009-26. PubMed ID: 25912721
[TBL] [Abstract][Full Text] [Related]
40. Polyethylene glycol prevents in vitro aggregation of slightly negatively-charged liposomes induced by heparin in the presence of bivalent ions.
Shibata H; Yomota C; Kawanishi T; Okuda H
Biol Pharm Bull; 2012; 35(11):2081-7. PubMed ID: 23123478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
